Search results
Author(s):
Leslee J Shaw
,
C Noel Bairey Merz
,
Steven E Reis
,
et al
Added:
3 years ago
Recent findings from landmark clinical trials, such as the Women's Health Initiative (WHI)1,2, have significantly altered current thinking about the role of postmenopausal hormone therapy (HT) in cardiovascular disease (CVD) prevention. HT was a therapy widely accepted by women and physicians, often used for CVD prevention purposes, based on observational epidemiologic data and plausible…
View more
The Evolution of Lead Extraction
Author(s):
Melanie Maytin
,
Laurence M Epstein
Added:
3 years ago
Article
Author(s):
Myung H Park
Added:
3 years ago
Author(s):
Somsupha Kanjanauthai
,
Kabir Bhasin
,
Luigi Pirelli
,
et al
Added:
3 years ago
Transcatheter aortic valve replacement (TAVR) has been established as a therapeutic option for patients with severe symptomatic aortic stenosis who are considered to be of intermediate, high or prohibitive surgical risk.1–5 As a result of favorable TAVR outcomes and substantial improvements in transcatheter heart valve (THV) technologies and implantation techniques, the feasibility of broadening…
View more
Author(s):
Sebastian Kelle
,
Eike Nagel
Added:
3 years ago
Cardiovascular magnetic resonance imaging (MRI) has moved from niche applications to the center of cardiovascular decision-making. Today, cardiovascular MRI offers several options for detecting ischemia in patients with known or suspected coronary artery disease (CAD). Over the last few years, much evidence has been accumulated of the diagnosis of CAD and heart failure with cardiovascular MRI.1–3…
View more
Author(s):
Antonio Gutierrez
,
Sunil V Rao
Added:
3 years ago
Current evidence-based therapies for ischemic heart disease include antithrombotic and antiplatelet medications that reduce the risk for ischemic outcomes such as myocardial infarction and stroke.1 Given their mechanism of action, bleeding is a risk with these agents, especially when combined with invasive procedures.2 In addition to overt bleeding, clinical trials of antithrombotic strategies…
View more
Author(s):
Bon-Kwon Koo
Added:
1 year ago
In this short interview from our coverage of ACC.22 late-breaking trials, Dr Bon Kwon Koo (Seoul National University Hospital, KR) discusses the FLAVOUR trial (NCT02673424).
FLAVOUR was a multicentre, non-inferiority, randomised clinical trial which sought to compare the safety and efficacy of FFR-guided stenting and IVUS-guided stenting. Presented first at ACC.22, the trial demonstrated that…
View more
Joost Daemen
Job title: Interventional Cardiologist
Author
Gender Disparities in PAD
Author(s):
Andrea Martinez
,
Jingwen Huang
,
Arash Harzand
Added:
1 month ago
Article
Author(s):
Ariana Traub
,
Apoorva Sharma
,
Maria Carolina Gongora
Added:
1 month ago